Led wrote: "...is it possible that we might get an indication with the FA if one of the SOC statins is better than the other?"

Hmmmmm. Good question. I asked Sarah a while back "Is there a pre-defined comparison between those patients on rosuvastatin vs. atorvastatin, or will that comparison be a post-hoc analysis after BETonMACE has ended?" and she responded "yes the rosuvastatin/atorvastatin will be a pre-specified analysis." However, the comparison of the two statins isn't mentioned on ClinicalTrials.gov. My guess is that the rosuvastatin vs. atorvastatin comparison is likely a secondary outcome/comparison and not the primary outcome/comparison. I expect the futility analysis to be focused on the primary outcome/comparison, which is apabetalone vs. placebo regardless of statin type. So no, I don't expect the FA to give an indication of one statin working better than the other.

BearDownAZ